Group 1 - The core point of the news is the performance and financial details of Beijing Baipusi Biotechnology Co., Ltd., which saw a stock price increase of 5.34% to 59.20 CNY per share, with a total market capitalization of 9.937 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and other supplementary services (1.80%) [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Baipusi, with its Penghua Guozheng 2000 Index Enhanced A fund holding 18,800 shares, representing 1.11% of the fund's net value, making it the largest holding [2] - The fund has achieved a year-to-date return of 40.3%, ranking 646 out of 4,218 in its category, and a one-year return of 61.95%, ranking 259 out of 3,865 [2]
百普赛斯股价涨5.34%，鹏华基金旗下1只基金重仓，持有1.88万股浮盈赚取5.64万元